nosocomial pneumonia

Ceftazidimeavibactam use in children and adolescents

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):173-183
10.36488/cmac.2021.2.173-183
The increasing number of infections caused by multidrug-resistant gram-negative bacteria in children is a serious problem all over the world. Ceftazidim-avibactam is a promising antimicrobial drug recently approved in Russia for use in pediatric …

Antimicrobial resistance of Gram-negative pathogens of nosocomial pneumonia in intensive care unit patients

Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(1):62-68
10.36488/cmac.2019.1.62-68
In order to study etiology and antimicrobial resistance rates in Gram-negative pathogens of nosocomial pneumonia, a total of 1410 isolates obtained from sputum in 75 ICU patients with nosocomial pneumonia in 2012 and 2017 was tested. The most common …

Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(2):127-145
Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) …

Nosocomial Pneumonia: Current State of Epidemiology, Diagnostics and Treatment

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(2):143-153
Nosocomial pneumonia (NP) is a serious challenge for modern medicine. NP leads to prolongation of the hospitalization and high mortality. Optimal approaches to the diagnosis and prophylaxis of NP remain subjects for further developmnet. Adequate and …

Nosocomial Pneumonia in Adults: Guidelines for the Diagnosis, Treatment and Prophylaxis

Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(1):4-31